Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tasly Pharma Selects ICON for Global Phase III Trial of TCM Heart Drug

publication date: Nov 21, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tasly Pharmaceuticals has chosen ICON, the Dublin-based CRO, to conduct a global Phase III trial of Tasly’s oral TCM treatment for angina. The drug, known alternately as T89, Dantonic® and Cardiotonic, could be the first TCM to win FDA approval in the US. In June of this year, Tasly announced it would invest $40 million into a US facility to support Dantonic. More details....

Stock Symbols: (SHA: 600535) (NSDQ: ICLR)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...